Internet-Delivered Cognitive Behaviour Therapy for Women with Perimenopausal Anxiety
Developing an Internet-Delivered Cognitive Behaviour Therapy Program for Women with Perimenopausal Anxiety: a Feasibility and Acceptability Study
1 other identifier
interventional
25
1 country
2
Brief Summary
The goal of this clinical trial is to design an online Cognitive Behavioural Therapy (CBT) and Acceptance Commitment Therapy (ACT) program and to learn if it can treat anxiety in women transitioning into menopause (perimenopause). The main questions it aims to answer are:
- Is our online psychotherapy program a practical and acceptable means of managing anxiety during perimenopause?
- Does our online psychotherapy program work in improving anxiety levels during perimenopause? Participants will participate in weekly e-CBT module sessions tailored to perimenopausal anxiety and will be given weekly feedback on assignments from trained care providers through a secure online platform. Participants will complete questionnaires at the beginning, middle, and at end of the study, as well as at the three and six-month follow-up.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2024
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 11, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2025
CompletedFirst Submitted
Initial submission to the registry
March 3, 2025
CompletedFirst Posted
Study publicly available on registry
March 7, 2025
CompletedMarch 7, 2025
February 1, 2025
4 months
March 3, 2025
March 3, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in symptoms (Generalized Anxiety Disorder - 7 Item)
Clinically validated symptom questionnaire. Scale of 0-3, 3 being the worst.
Week 0, week 4, week 9, 3 and 6-month follow-up
Secondary Outcomes (7)
Change in symptoms (Menopausal Rating Scale)
Week 0, week 4, week 9, 3 and 6-month follow-up
Change in symptoms (Depression Anxiety Scale - 21 Item)
Week 0, week 4, week 9, 3 and 6-month follow-up
Change in symptoms (The Menopause-specific Quality of Life)
Week 0, week 4, week 9, 3 and 6-month follow-up
Change in symptoms (Center for Epidemiologic Studies Depression Scale)
Week 0, week 4, week 9, 3 and 6-month follow-up
Change in symptoms (Pittsburgh Sleep Quality Index)
Week 0, week 4, week 9, 3 and 6-month follow-up
- +2 more secondary outcomes
Study Arms (1)
Online psychotherapy treatment arm
EXPERIMENTALAll participants will receive access to e-CBT modules offered through the Online Psychotherapy Tool (OPTT) and will be paired with an online careprovider, who is trained to administer online CBT and ACT. Following the structure of previous e-CBT modules developed by the QUOPL team, the module for this study will be designed to mirror standard in-person CBT for Generalized Anxiety Disorder and will combine components of ACT. Weekly homework will be assigned and evaluated by the participant's designated care provider, who will provide personalized feedback on the online platform (OPTT), acknowledging their module completion and homework
Interventions
Electronically delivered cognitive behavioural therapy with acceptance commitment therapy components
Eligibility Criteria
You may qualify if:
- In perimenopausal staging (as defined by the STRAW +10 criteria)
- Assigned female at birth
- Diagnosis of GAD according to DSM-5 by attending psychiatrist on research team
- Competence to consent to participate
- Ability to speak and read English
- Consistent and reliable access to the internet
You may not qualify if:
- Undergone CBT or hormone therapy within the last 6 months will be excluded
- Active psychosis
- Acute mania
- Severe alcohol or substance use disorder
- Active suicidal or homicidal ideation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Kingston General Hospital
Kingston, Ontario, K7L 5G3, Canada
Nazanin Alavi
Kingston, Ontario, K7L 5G3, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nazanin Alavi, MD, FRCPC
Queen's University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator, Assistant Professor
Study Record Dates
First Submitted
March 3, 2025
First Posted
March 7, 2025
Study Start
November 11, 2024
Primary Completion
February 28, 2025
Study Completion
February 28, 2025
Last Updated
March 7, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share
Results will be shared through conference presentations, workshops, and journal publications.